Cargando…
Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for therapeutic intervention, since they may act as biomarkers or key regulators of cancer gene network. Recently, pro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305591/ https://www.ncbi.nlm.nih.gov/pubmed/32563270 http://dx.doi.org/10.1186/s13046-020-01622-x |
_version_ | 1783548494959607808 |
---|---|
author | Grillone, Katia Riillo, Caterina Scionti, Francesca Rocca, Roberta Tradigo, Giuseppe Guzzi, Pietro Hiram Alcaro, Stefano Di Martino, Maria Teresa Tagliaferri, Pierosandro Tassone, Pierfrancesco |
author_facet | Grillone, Katia Riillo, Caterina Scionti, Francesca Rocca, Roberta Tradigo, Giuseppe Guzzi, Pietro Hiram Alcaro, Stefano Di Martino, Maria Teresa Tagliaferri, Pierosandro Tassone, Pierfrancesco |
author_sort | Grillone, Katia |
collection | PubMed |
description | The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for therapeutic intervention, since they may act as biomarkers or key regulators of cancer gene network. Recently, profiling and sequencing of ncRNAs disclosed deep deregulation in human cancers mostly due to aberrant mechanisms of ncRNAs biogenesis, such as amplification, deletion, abnormal epigenetic or transcriptional regulation. Although dysregulated ncRNAs may promote hallmarks of cancer as oncogenes or antagonize them as tumor suppressors, the mechanisms behind these events remain to be clarified. The development of new bioinformatic tools as well as novel molecular technologies is a challenging opportunity to disclose the role of the “dark matter” of the genome. In this review, we focus on currently available platforms, computational analyses and experimental strategies to investigate ncRNAs in cancer. We highlight the differences among experimental approaches aimed to dissect miRNAs and lncRNAs, which are the most studied ncRNAs. These two classes indeed need different investigation taking into account their intrinsic characteristics, such as length, structures and also the interacting molecules. Finally, we discuss the relevance of ncRNAs in clinical practice by considering promises and challenges behind the bench to bedside translation. |
format | Online Article Text |
id | pubmed-7305591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73055912020-06-22 Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” Grillone, Katia Riillo, Caterina Scionti, Francesca Rocca, Roberta Tradigo, Giuseppe Guzzi, Pietro Hiram Alcaro, Stefano Di Martino, Maria Teresa Tagliaferri, Pierosandro Tassone, Pierfrancesco J Exp Clin Cancer Res Review The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for therapeutic intervention, since they may act as biomarkers or key regulators of cancer gene network. Recently, profiling and sequencing of ncRNAs disclosed deep deregulation in human cancers mostly due to aberrant mechanisms of ncRNAs biogenesis, such as amplification, deletion, abnormal epigenetic or transcriptional regulation. Although dysregulated ncRNAs may promote hallmarks of cancer as oncogenes or antagonize them as tumor suppressors, the mechanisms behind these events remain to be clarified. The development of new bioinformatic tools as well as novel molecular technologies is a challenging opportunity to disclose the role of the “dark matter” of the genome. In this review, we focus on currently available platforms, computational analyses and experimental strategies to investigate ncRNAs in cancer. We highlight the differences among experimental approaches aimed to dissect miRNAs and lncRNAs, which are the most studied ncRNAs. These two classes indeed need different investigation taking into account their intrinsic characteristics, such as length, structures and also the interacting molecules. Finally, we discuss the relevance of ncRNAs in clinical practice by considering promises and challenges behind the bench to bedside translation. BioMed Central 2020-06-20 /pmc/articles/PMC7305591/ /pubmed/32563270 http://dx.doi.org/10.1186/s13046-020-01622-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Grillone, Katia Riillo, Caterina Scionti, Francesca Rocca, Roberta Tradigo, Giuseppe Guzzi, Pietro Hiram Alcaro, Stefano Di Martino, Maria Teresa Tagliaferri, Pierosandro Tassone, Pierfrancesco Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” |
title | Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” |
title_full | Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” |
title_fullStr | Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” |
title_full_unstemmed | Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” |
title_short | Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” |
title_sort | non-coding rnas in cancer: platforms and strategies for investigating the genomic “dark matter” |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305591/ https://www.ncbi.nlm.nih.gov/pubmed/32563270 http://dx.doi.org/10.1186/s13046-020-01622-x |
work_keys_str_mv | AT grillonekatia noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT riillocaterina noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT sciontifrancesca noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT roccaroberta noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT tradigogiuseppe noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT guzzipietrohiram noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT alcarostefano noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT dimartinomariateresa noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT tagliaferripierosandro noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter AT tassonepierfrancesco noncodingrnasincancerplatformsandstrategiesforinvestigatingthegenomicdarkmatter |